A residual mass after treatment of lymphoma is a clinical challenge, because it may
represent vital tumor as well as tissue fibrosis. Metabolic imaging by 18F …

Positron emission tomography (PET) imaging has become a very useful technique for
staging and monitoring therapy response in lymphoma, providing unique information about …

Abstract Until recently, gallium-67 scintigraphy (GS) has been the best available functional
imaging modality for evaluating patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's …

Residual mediastinal masses are frequently observed in patients with Hodgkin disease (HD)
after completed therapy, and the discrimination between active tumor tissue and fibrotic …

BACKGROUND The accuracy of fluorodeoxyglucose positron emission tomography (FDG‐
PET; dual‐head camera with attenuation correction) and Ga‐67 scintigraphy was compared …

Purpose The value of 18 FDG-PET to predict the outcome after therapy in Hodgkin's
lymphoma was compared to morphologic staging and ESR Patients and methods A total of …

Background PET using 18 fluorodesoxyglucose (FDG) may offer the possibility of
differentiating vital from necrotic residual masses. Patients and methods Seventeen patients …

An extensive analysis of the reliability of positron emission tomography (PET) after induction
treatment in patients with Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma …

Lymphoma is a complex disease that arises from cells of the immune system with an
intricate pathology. While lymphoma may be classified as Hodgkin or non-Hodgkin, each …

To assess the potential value of magnetic resonance (MR) imaging in monitoring disease
status, 34 patients with residual masses underwent MR imaging at sequential intervals …